Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17893191 | 1.00 | FFAR3 (0.77) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL17893188 | 1.00 | FFAR3 (0.77) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL17893172 | 0.88 | FFAR3 (0.60) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL405480 | 0.87 | FFAR3 (0.65) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL4442780 | 0.87 | FFAR3 (0.65) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL14012097 | 0.87 | FFAR3 (0.65) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL13490845 | 0.87 | FFAR3 (0.65) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL503244 | 0.87 | FFAR3 (0.65) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL25276733 | 0.87 | FFAR3 (1.00) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL3671602 | 0.87 | FFAR3 (1.00) | FFAR3MAPK1TP53NFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3240546-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240572-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109223-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | FFAR3 2896/4885MAPK1 529/4885TP53 1569/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | FFAR3 2896/4885MAPK1 529/4885TP53 1569/4885 |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | BTK, SYK, ABL1 | FFAR3 1860/4885MAPK1 315/4885TP53 1639/4885 |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | FFAR3 1860/4885MAPK1 315/4885TP53 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.